摘要
目的分析瑞舒伐他汀辅以替格瑞洛对经皮冠状动脉介入(PCI)老年冠心病患者心功能及血脂水平的影响。方法选取2016年1月—2018年3月于东南大学附属中大医院就诊并接受冠状动脉支架植入术的老年冠心病患者128例。采用随机数字表法将所选患者分为观察组和对照组,每组64例。入院后所有患者均给予基础治疗。此外,对照组术前口服瑞舒伐他汀+阿司匹林+氯吡格雷治疗,观察组术前口服瑞舒伐他汀+阿司匹林+替格瑞洛治疗,2组均持续用药6个月。比较2组血脂水平、再狭窄率、心功能指标及血小板聚集功能,并记录心血管不良事件的发生情况。结果PCI治疗后6个月,2组总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白-胆固醇(LDL-C)均较治疗前显著降低(P<0.05),而高密度脂蛋白胆固醇(HDL-C)较治疗前显著升高(P<0.05)。对照组发生2例再狭窄,观察组发生1例再狭窄,差异无统计学意义(P>0.05)。PCI治疗6个月后,2组左心室射血分数(LVEF)水平均较治疗前显著提高,氨基末端脑钠肽前体(NT-BNP)水平较治疗前显著降低,差异有统计学意义(P<0.05);与同期对照组比较,观察组LVEF明显升高、NT-BNP明显降低,差异有统计学意义(P<0.05)。PCI治疗6个月后,2组血小板最大聚集率均较治疗前显著降低,差异有统计学意义(P<0.05);与同期对照组比较,观察组血小板最大聚集率明显降低,差异有统计学意义(P<0.05)。观察组心血管不良事件的总发生率明显低于对照组(P<0.05)。结论对经PCI治疗的老年冠心病患者开展瑞舒伐他汀辅以替格瑞洛的联合治疗,可有效减少再狭窄的发生率,改善血脂和心功能,提高抗血小板聚集作用,安全性较高。
Objective To analyze the effects of resuvastatin and tigrelol on the cardiac function and blood lipid of coronary heart disease patients treated by percutaneous coronary intervention(PCI).Methods A total of 128 coronary heart disease patients were selected,who were admitted into Zhongda Hospital Affiliated to Southeast University from January 2016 to March 2018 and underwent coronary stent implantation.According to the random number table method,they were randomly divided into two groups(n=64):an observation group and a control group.After admission,all patients received basic treatment.Furthermore,the control group was orally taken resuvastatin+biaspirin+clopidogrel before surgery,while the observation group was orally taken resuvastatin+biaspirin+tigrelol before surgery.Both groups were continuously treated with resuvastatin for 6 months.Then,the two groups were compared for blood lipid level,restenosis rate,cardiac function index and platelet aggregation function,and cardiovascular adverse events were recorded.Results Six months after PCI treatment,remarkably decreased laveles of TC,TG and LDL-C and marked increased laveles of HDL-C were found in the two groups compared with pre-treatment levels(P<0.05).There were two cases of restenosis in the control group and one case of restenosis in the observation group,without statistical difference(P>0.05).Six months after PCI treatment,both groups presented significantly higher levels of left ventricular ejection fraction(LVEF)and markedly lower levels of N-terminal pro-BNP(NT-BNP)compared with pre-treatment levels(P<0.05).Compared with the control group,the observation group produced significantly increased LEVF and decreased NT-BNP,with statistical difference(P<0.05).Six months after PCI treatment,both groups presented remarkable decreases in the maximum platelet aggregation rate compared with pre-treatment levels(P<0.05)。Compared with the control group in the same period,the maximum platelet aggregation rate in the observation group was significantly lower(P<0.05
作者
张启杰
鄢高亮
焦慧
邵良发
杨宏飞
ZHANG Qijie;YAN Gaoliang;JIAO Hui;SHAO Liangfa;YANG Hongfei(Department of Cardiovascular Medicine,Jiangbei Branch,Zhongda Hospital Affiliated to Southeast University,Nanjing,Jiangsu 210000,China;Department of Cardiovascular Medicine,Zhangda Hospital Affiliated to Southeast University,Nanjing,Jiangsu 210000;Department of Neurology,Jiangbei Branch,Zhongda Hospital Affiliated to Southeast University)
出处
《徐州医科大学学报》
CAS
2020年第4期250-254,共5页
Journal of Xuzhou Medical University
基金
国家自然科学基金(81600227)。
关键词
经皮冠状动脉介入
瑞舒伐他汀
替格瑞洛
心功能
血小板聚集
percutaneous coronary intervention
risuvastatin
tigrello
blood lipid
cardiac function
platelet aggregation
